Recent news on Epinastine

Inspire Announces Positive Results of Phase 2 Trial of Epinastine ...  -  May 9, 2007
PipelineReview.com (press release),Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced results of a Phase 2 dose-ranging clinical trial comparing epinastine nasal spray and placebo

Inspire Gets Good Result for Nasal Spray  -  May 8, 2007
Forbes,The study found the higher of two doses of epinastine nasal spray improved allergy symptoms more than a placebo. Inspire said it will now begin a six-month

Inspire Announces Webcasts of Presentations at Deutsche Bank and ...  -  26 Apr 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Inspire to Present Data at 2007 American Academy of Allergy ...  -  Feb 23, 2007
PharmaLive.com (press release),Inspire is developing two treatments for allergic rhinitis, including bilastine, an oral antihistamine in Phase 3 development, and epinastine nasal spray,

Inspire Announces Webcast of Presentation at Susquehanna ...  -  Feb 22, 2007
PharmaLive.com (press release),Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine

Inspire Pharmaceuticals annonces executive management promotions ...  -  Feb 20, 2007
Carolina Newswire (press release),Inspire’s US specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine

Inspire Licenses AzaSite ™ For Ocular Infections  -  Feb 16, 2007
Business Wire (press release),Inspire’s US specialty sales force promotes Elestat ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis ® (cyclosporine

Inspire provides Cystic Fibrosis clinical program update  -  18 Jan 2007
Carolina Newswire (press release),Inspire’s US specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine

Inspire Announces Dry Eye Program Update  -  Jan 4, 2007
PharmaLive.com (press release),Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 6, 2006
dBusinessNews Triad (press release),This Phase 2 clinical trial is a 14-day randomized, double-blind comparison of two doses of epinastine nasal spray (0.05% and 0.1%) to placebo in

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 5, 2006
PipelineReview.com (press release),Announced today the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis.

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 5, 2006
Genetic Engineering News (press release),Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment

Inspire Pharmaceuticals' Shares, 'Inspired' By Clinical Trial ...  -  Dec 6, 2006
Seeking Alpha,..."With the initiation of this trial, we are making excellent progress in our epinastine nasal spray development program," stated Christy L. Shaffer, Ph.D.,

Inspire shares rise 19% on clinical trial update  -  Dec 10, 2006
Bizjournals.com,...has climbed more than 19 percent since the company announced Wednesday that it has initiated phase II clinical trials for its epinastine nasal spray.

Market Report -- In Play (WIRES)  -  Dec 5, 2006
MSN MoneyInspire Pharmaceuticals (ISPH) announces the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal

Inspire Begins Phase 2 Clinical Program of Epinastine for Seasonal ...  Oct 10, 2006
...(NASDAQ: ISPH) announced today that an investigational new drug application (IND) for epinastine nasal spray has been filed with the US Food and Drug ... -Business Wire (press release), Inspire Begins Phase 2 Clinical Program of Epinastine for Seasonal ...  Oct 10, 2006
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that an investigational new drug application (IND) for epinastine nasal spray has been filed with ... -Genetic Engineering News (press release), ISPH: Files IND for Epinastine Nasal Spray; Begins Ph 2 Trial for ...  Oct 10, 2006
...(ISPH) announced that an IND for epinastine nasal spray has been filed with the FDA and is in effect, having passed the 30-day review period. ... -Therapeutics Daily (subscription) (press release), Inspire Pharma Initiates Phase 2 Clinical Study Of Epinastine On ...  Oct 10, 2006
...charts | news | PowerRating), a bio-pharmaceutical company, revealed that it has filed an investigational new drug application for epinastine nasal spray with ... -Trading Markets, Inspire Begins Phase 2 Clinical Program of Epinastine for Seasonal ...  Oct 11, 2006
Announced today that an investigational new drug application (IND) for epinastine nasal spray has been filed with the US Food and Drug Administration (FDA) and ... -PipelineReview.com (press release), Inspire Begins Phase 2 Clinical Program of Epinastine for Seasonal ...  Oct 10, 2006
...announced today that an investigational new drug application (IND) for epinastine nasal spray has been filed with the US Food and Drug Administration (FDA) and ... -dBusinessNews Triangle (press release), Inspire Reports Third Quarter 2006 Financial Results  Nov 7, 2006
Co-promotion revenue from net sales of Elestat(R) (epinastine HCl ophthalmic solution) 0.05% was $5.4 million, an increase of 20% compared to $4.5 million ... -PharmaLive.com (press release), Inspire Gains Phase III-Stage Allergy Drug Via $89M Deal  Nov 1, 2006
In addition to Elestat (epinastine HCl ophthalmic solution), which Inspire markets for Irvine, Calif.-based Allergan Inc., the company is developing a nasal ... -BioWorld Online, Inspire Announces Progress in Cystic Fibrosis Program  Nov 3, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -Genetic Engineering News (press release), Inspire and FAES Farma Announce Licensing Agreement for New Oral ...  Nov 2, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -PipelineReview.com (press release), Inspire announces progress in Cystic Fibrosis Program  Nov 3, 2006
Inspire’s US specialty sales force promotes Elestat® (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ... -Carolina Newswire (press release), Inspire Pharma Commences Phase 2 Clinical Program For Seasonal ...  Oct 10, 2006
...(ISPH | charts | news | PowerRating) on Tuesday said that an investigational new drug application for epinastine nasal spray, has been filed with the FDA, and ... -Trading Markets, Market Report -- In Play (WIRES)  Oct 10, 2006
On The Wires Inspire Pharmaceuticals (ISPH) announces that an investigational new drug application for epinastine nasal spray has been filed with the FDA and ... -MSN Money Inspire Announces Webcasts of Presentations at UBS and Noble ...  Sep 19, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -Business Wire

Inspire shares rise 19% on clinical trial update  -  Dec 10, 2006
Washington Business Journal,...has climbed more than 19 percent since the company announced Wednesday that it has initiated phase II clinical trials for its epinastine nasal spray. ...

Inspire Initiates Phase 2 14-Day Clinical Trial of Epinastine for ...  -  Dec 5, 2006
Business Wire (press release),...(NASDAQ: ISPH) announced today the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis. ...

Inspire Pharmaceuticals (ISPH) to Initiate Phase 2 Trials of ...  -  Dec 5, 2006
StreetInsider.com (subscription),...(NASDAQ: ISPH) announced the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis. ...

Inspire Pharmaceuticals Upswing Day 2  -  Dec 6, 2006
Ant & SonsInspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced yesterday the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the ...

StreetInsider.com Unusual 11 Mid-Day Movers 12/06/06  -  Dec 6, 2006
StreetInsider.com (subscription),Nasdaq: ISPH) 12.5% HIGHER; Stock moved up 6% yesterday after announcing the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the ...

Inspire Terminating Phase II Trial Of INS50589 Antiplatelet  Aug 8, 2006
At the earlier stage, Inspire is developing intranasal epinastine, which it in-licensed from Boehringer Ingelheim International GmbH, of Ingelheim, Germany, in ... -BioWorld Online

Inspire Terminates Phase 2 Clinical Trial for Platelet Aggregation ...  Aug 8, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -PipelineReview.com

Troubles mount at drug company  Aug 9, 2006
FEBRUARY 2006: Inspire buys the rights to develop and market a nasal spray of epinastine, an allergy drug made by German-based Boehringer Ingelheim ... -News & Observer

Inspire Reports Second Quarter 2006 Financial Results; Second ...  Aug 8, 2006
Co-promotion revenue from net sales of Elestat(R) (epinastine HCl ophthalmic solution) 0.05% was $9.4 million, an increase of 19% compared to $7.9 million ... -Business Wire

Inspire Initiates Phase 3 Clinical Trial of Denufosol Tetrasodium ...  Jul 27, 2006
Inspire's US specialty sales force promotes Elestat(R)(epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitisand Restasis(R) (cyclosporine ... -Finanzen.net

Inspire Announces Webcast of Presentation At CE Unterberg, Towbin ...  Jul 5, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ... -Business Wire



Inspire Reports First Quarter 2006 Financial Results; Co-Promotion ...  May 9, 2006
Total co-promotion revenue for the first quarter of 2006 included $1.3 million from net sales of Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and $2.9 ... - Business Wire

Inspire Announces Webcasts of Presentations at Two Healthcare ...  Apr 24, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05 ... - Genetic Engineering News





Inspire Announces Outcome of FDA Meeting on Dry Eye Program ...  Mar 28, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05 ... - Genetic Engineering News

Inspire to Present at Southeast Invest 2006 Conference  Mar 31, 2006
...technical. cardiovascular disease. Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05%. Inc. ... - dBusinessNews Triangle

Inspire Announces Development and License Agreement with ...  Feb 21, 2006
Inspire will acquire certain exclusive rights to develop and market an intranasal dosage form of epinastine in the United States and Canada for the treatment ... - Genetic Engineering News,

Inspire to Present at 26th Annual Cowen Health Care Conference  Feb 28, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05 ... - Genetic Engineering News,

Inspire Licenses Drug Development Deal With German Firm  Feb 21, 2006
...conditions. Inspire wants to develop an intranasal dosage form of epinastine, the active drug substance it is licensing. Inspire ... - Local Tech Wire,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional